Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate
Author:
Funder
Chugai Pharmaceutical Co., Ltd
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
http://link.springer.com/article/10.1007/s00280-019-03768-8/fulltext.html
Reference37 articles.
1. Chan E, Berlin J (2015) Biliary tract cancers: understudied and poorly understood. J Clin Oncol 33(16):1845–1848. https://doi.org/10.1200/jco.2014.59.7591
2. Recio-Boiles A, Babiker HM (2017) Cancer, gallbladder. In: StatPearls. StatPearls, Treasure Island
3. Furuse J, Okusaka T (2011) Targeted therapy for biliary tract cancer. Cancers (Basel) 3(2):2243
4. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127. https://doi.org/10.1038/35052073
5. Wang Z (2017) ErbB receptors and cancer. In: Wang Z (ed) ErbB receptor signaling: methods and protocols. Springer, New York, pp 3–35. https://doi.org/10.1007/978-1-4939-7219-7_1
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives;Cancers;2023-07-20
2. Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers;Frontiers in Molecular Biosciences;2023-05-11
3. Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report;Frontiers in Oncology;2022-07-07
4. Anti-Glypican-1 Antibody–drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1–Positive Cholangiocarcinoma;Molecular Cancer Therapeutics;2021-06-17
5. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview;OncoTargets and Therapy;2021-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3